New “Trojan horse” obesity drug supercharges weight loss in early tests

Researchers led by metabolism expert Prof Timo D. Müller at Helmholtz Munich have developed a new strategy to treat obesity and type 2 diabetes. Their approach uses a specially designed hybrid molecule that takes advantage of the well-known GLP-1/GIP signalling pathway as a kind of entry point into cells. Once inside, it delivers an additional metabolic compound directly where it is needed.

1. Homepage
2. Science
3. New “Trojan horse” obesity drug supercharges weight loss in early tests